[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcTv_QMalfPI8TOptTREjUYrehSXqn6xNQymjvrsdqqs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":33,"rows":40},"University Hospitals Coventry and Warwickshire NHS Trust",[4],55,false,10,0,10083,49,[13,16,19,21,23,25,27,30],{"name":14,"count":15},"Stroke",3,{"name":17,"count":18},"Obstructive Sleep Apnea",2,{"name":20,"count":18},"Colorectal Cancer",{"name":22,"count":18},"Critical Illness",{"name":24,"count":18},"Intubation, Intratracheal",{"name":26,"count":18},"Obesity",{"name":28,"count":29},"Live Donors, Ethnic Minorities, Transplantation",1,{"name":31,"count":29},"Topical Corticosteroid-treated Dermatology Patients",[],[34,35,36,37,38,39],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[41,69,87,111,138,156,182,208,234],{"intervention":42,"totalTrials":29,"cells":43},"IMU-838",{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":48,"PHASE3":63,"PHASE4":65,"NA":67},{"trials":45,"activeCount":9},[],{"trials":47,"activeCount":9},[],{"trials":49,"activeCount":9},[50],{"nctId":51,"briefTitle":52,"status":53,"phases":54,"primaryCompletion":55,"completion":56,"start":57,"enrollment":58,"conditions":59,"interventions":61},"NCT04516915","IMU-838 and Oseltamivir in the Treatment of COVID-19","COMPLETED",[36],"2022-05-20","2022-09-21","2020-06-15",38,[60],"Covid 19",[42,62],"Oseltamivir",{"trials":64,"activeCount":9},[],{"trials":66,"activeCount":9},[],{"trials":68,"activeCount":9},[],{"intervention":62,"totalTrials":29,"cells":70},{"EARLY_PHASE1":71,"PHASE1":73,"PHASE2":75,"PHASE3":81,"PHASE4":83,"NA":85},{"trials":72,"activeCount":9},[],{"trials":74,"activeCount":9},[],{"trials":76,"activeCount":9},[77],{"nctId":51,"briefTitle":52,"status":53,"phases":78,"primaryCompletion":55,"completion":56,"start":57,"enrollment":58,"conditions":79,"interventions":80},[36],[60],[42,62],{"trials":82,"activeCount":9},[],{"trials":84,"activeCount":9},[],{"trials":86,"activeCount":9},[],{"intervention":88,"totalTrials":29,"cells":89},"Dexamethasone",{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":109},{"trials":91,"activeCount":9},[],{"trials":93,"activeCount":9},[94],{"nctId":95,"briefTitle":96,"status":53,"phases":97,"primaryCompletion":98,"completion":98,"start":99,"enrollment":8,"conditions":100,"interventions":102},"NCT03341676","Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)",[35],"2023-08-31","2019-01-14",[101],"High Altitude Cerebral Edema",[88],{"trials":104,"activeCount":9},[],{"trials":106,"activeCount":9},[],{"trials":108,"activeCount":9},[],{"trials":110,"activeCount":9},[],{"intervention":112,"totalTrials":29,"cells":113},"Potent topical steroid",{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":115,"activeCount":9},[],{"trials":117,"activeCount":9},[],{"trials":119,"activeCount":9},[],{"trials":121,"activeCount":9},[],{"trials":123,"activeCount":9},[],{"trials":125,"activeCount":9},[126],{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"NCT01759914","Ocular Pressure in Steroid-treated Dermatology Patients","TERMINATED",[],"2013-07","2012-09",25,[31,135],"Intra-ocular Pressure",[112,137],"Superpotent topical steroid",{"intervention":137,"totalTrials":29,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":150},{"trials":141,"activeCount":9},[],{"trials":143,"activeCount":9},[],{"trials":145,"activeCount":9},[],{"trials":147,"activeCount":9},[],{"trials":149,"activeCount":9},[],{"trials":151,"activeCount":9},[152],{"nctId":127,"briefTitle":128,"status":129,"phases":153,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":154,"interventions":155},[],[31,135],[112,137],{"intervention":157,"totalTrials":29,"cells":158},"Saxenda",{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":160,"activeCount":9},[],{"trials":162,"activeCount":9},[],{"trials":164,"activeCount":9},[],{"trials":166,"activeCount":9},[],{"trials":168,"activeCount":9},[],{"trials":170,"activeCount":9},[171],{"nctId":172,"briefTitle":173,"status":53,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":181},"NCT03885297","3mg Liraglutide for Overweight or Obesity",[],"2020-12-18","2019-01-18",43,[179,26,180],"Overweight","Infertility, Female",[157],{"intervention":183,"totalTrials":29,"cells":184},"Bupivacaine",{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":186,"activeCount":9},[],{"trials":188,"activeCount":9},[],{"trials":190,"activeCount":9},[],{"trials":192,"activeCount":9},[],{"trials":194,"activeCount":9},[],{"trials":196,"activeCount":9},[197],{"nctId":198,"briefTitle":199,"status":53,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":207},"NCT01528722","Randomized Control Trial of Intraperitoneal Bupivacaine During Cholecystectomy",[39],"2010-01","2009-01",42,[205,206],"Cholecystitis","Gall Stone Pancreatitis",[183],{"intervention":209,"totalTrials":29,"cells":210},"Bupivocaine",{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":221},{"trials":212,"activeCount":9},[],{"trials":214,"activeCount":9},[],{"trials":216,"activeCount":9},[],{"trials":218,"activeCount":9},[],{"trials":220,"activeCount":9},[],{"trials":222,"activeCount":9},[223],{"nctId":224,"briefTitle":225,"status":53,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT01090882","Intraperitoneal Techniques of Local Anaesthesia During Laparoscopic Cholecystectomy",[39],"2009-10","2009-07",128,[231],"Gall Stones",[209,233],"0.9% normal saline solution",{"intervention":233,"totalTrials":29,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":246},{"trials":237,"activeCount":9},[],{"trials":239,"activeCount":9},[],{"trials":241,"activeCount":9},[],{"trials":243,"activeCount":9},[],{"trials":245,"activeCount":9},[],{"trials":247,"activeCount":9},[248],{"nctId":224,"briefTitle":225,"status":53,"phases":249,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":250,"interventions":251},[39],[231],[209,233]]